LRMR Live signals | Maximize Profits with Getagraph.com

BUY 92498 min ago

@ $11.62

Issued: 14 Feb 2024 @ 13:41

Return: -45.07%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 25.70 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform...

Stats
Today's Volume	453 308
Average Volume	635 369
Market Cap	407.04M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.240 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.60
ATR14	$0.0220 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 206	Common Stock
2024-02-16	Flynn James E	Buy	1 430 205	Common Stock
2024-02-14	Thomas Frank E	Buy	2 000	Common Stock
2024-01-17	Shankar Gopi	Buy	135 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 20 937 267 \| Sell: 6 152 661

Volume Correlation

Long: -0.49 (neutral)

Short: -0.05 (neutral)

Signal:(41.345) Neutral

Larimar Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Larimar Therapeutics Inc Correlation - Currency/Commodity

-0.39
( neutral )

-0.61
( weak negative )

0.00
( neutral )

0.35
( neutral )

-0.39
( neutral )

Larimar Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-311 000 (0.00 %)
EPS:	$-0.840

Q4	2023
Revenue:	$0
Gross Profit:	$-81 000.00 (0.00 %)
EPS:	$-0.300

Q3	2023
Revenue:	$0
Gross Profit:	$-69 000.00 (0.00 %)
EPS:	$-0.210

Q2	2023
Revenue:	$0
Gross Profit:	$-49 000.00 (0.00 %)
EPS:	$-0.190

Financial Reports:

No articles found.

Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.